Tenofovir Alafenamide fumarate as known as GS-7340, CAS number is 379270-37-8 which is used to treat for compensatory liver disease in chronic hepatitis B, AIDS. It interferes with the function of hepatitis B virus DNA polymerase inhibition of hepatitis B virus replication, reducing serum and liver tissue viral load. it was formally approved for the treatment of chronic hepatitis B in 2016 year. GS-7340 is a prodrug of tenofovir, its treatment can be completely comparable with tenofovir, and has good bioavailability, dose and toxicity is far less than tenofovir. In the current treatment of hepatitis B in all drugs must comply with the principle of long-term use, in the course of medication if the sudden withdrawal may be an acute liver disease increased, or even liver failure. Therefore, the development of new drugs with high efficiency, low toxicity and high bioavailability, and how to prevent and reduce the incidence of drug resistance is a hotspot in the research and application of anti-HBV drugs. Therefore, the clinical advantages of Tenofovir Alafenamide fumarate (TAF) came into being.

Thera. Category:  Anti-HIV

Cas No.:379270-37-8 

Synonym: GS-7340;Tenofovir alafenamide hemifumarate;(S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl);GS-7340/GS7340;Tenofovir Alafenamide fumarate, N-[[S(P)]-[2-(Adenin-9-yl)-1(R)-methylethoxymethyl](phenoxy)phosphoryl]-L-alanine isopropyl ester;Tenofovir Alafenamide fumarate;(S)-Isopropyl 2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate;Tenofovir Alafenamide (GS-7340);

Molecular Formula:C21H29N6O5P

Molecular Weight:476.465921

Purity: ≥98.%

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

 Tenofovir alafenamide, also known as TAF and GS-7340, is a nucleotide reverse transcriptase inhibitor (NRTIs) and a novel prodrug of tenofovir. By blocking reverse transcriptase, TAF prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. In the body, tenofovir alafenamide is converted to tenofovir diphosphate (TFV-DP). Tenofovir alafenamide fumarate was approved in November 2015 for treatment of HIV-1.

Related Intermediate:
1) Phenyl ((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate 379270-35-6
2) GS-7340 intermediate 379270-36-7
3) GS-7340 CAS 379270-37-8
4) Tenofovir alafenamide hemifumarate CAS 1392275-56-7